Early Adoption of Anti–SARS-CoV-2 Pharmacotherapies Among Veterans With Mild to Moderate COVID-19

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), FRIDAY, NOVEMBER 11, 2022

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.41434?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=111122

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: In this study of more than 111,000 veterans who tested positive for SARS-CoV-2 during January and February 2022 when supply of outpatient COVID-19 pharmacotherapies was limited, prescription of these pharmacotherapies was underused, and many veterans with risk factors for severe COVID-19 did not receive treatment. Veterans from minority racial and ethnic groups were less likely to receive any pharmacotherapy. 

Authors: Kristina L. Bajema, M.D., M.Sc., of the Veterans Affairs Portland Health Care System in Portland, Oregon, is the corresponding author.

 

(doi:10.1001/jamanetworkopen.2022.41434)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.